Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury?

• Rolf Teschke
• Wolff A.
• Eickhoff A.
• Danan G.

Abstract

Acute Liver injury has been attributed to dietary supplements (DS) used for weight Loss, but their causal role was much questioned, and obesity as an alternative cause of the liver injury remained unclear. A comprehensive search of the Medline database was conducted with terms that included "DS", "liver injury", "obesity", "obesityrelated liver diseases", and "nonalcoholic steatohepatitis". For each term, we focused on the first 50 publications. We undertook a manual search to identify additional reports. Underlying liver diseases and other health issues are common in patients taking DS for weight reduction. These include obesity or morbid obesity, as well as complex metabolic disorders complicated by excess morbidity and mortality due to associated liver diseases. Among these are nonalcoholic fatty liver disease with potential progression to nonalcoholic steatohepatitis and cirrhosis, often classified as cryptogenic with a rare risk of hepatocellular carcinoma. With the exception of hepatocellular carcinoma, these obesity-related liver diseases were observed to varying degrees in patients, and some even required a liver transplant. This raises the question whether the liver injury that occurred in these patients is due to DS consumed for weight loss or to the underlying obesity-related liver diseases. This analysis showed that, in many instances, the causal role of obesity has been neglected. Obesity-associated liver diseases should be considered as differential diagnosis of liver injury in obese patients using DS.

Keywords:dietary supplements, green tea extract, Herbalife, Hydroxycut, liver injury, liver transplantation, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, obesity, OxyELITE Pro

REFERENCES

1. Sarges P., Steinberg J.M., Lewis J.H. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016; 39: 561–75. DOI: https://doi.org/10.1007/s40264-016-0427-8

2. Shahbaz O., Mahajan S., Lewis J.H. Highlights of drug- and herbinduced liver injury in the literature from 2016: how best to translate new information into clinical practice? Exp Opin Drug Metab Toxicol. 2017; 13: 935–51. DOI: https://doi.org/10.1080/17425255.2017.1362391 (date of access November 10, 2017)

3. Brown A. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. Food Chem Toxcol. 2017; 107: 472–501.

4. Teschke R., Andrade R.J. Editorial. Special issue «drug, herb, and dietary supplement hepatotoxicity». Int J Mol Sci. 2016; 17: 1488. DOI: https://doi.org/10.3390/ijms17091488 URL: http://www.mdpi.com/journal/ijms/special_issues/Hepatotoxicity (date of access November 10, 2017)

5. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016; 17: 14. DOI: https://doi.org/10.3390/ijms17010014

6. Björnsson E.S. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016; 17: 224. DOI: https://doi.org/10.3390/ijms17020224

7. Frenzel C., Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci. 2016; 17: 588. DOI: https://doi.org/10.3390/ijms17050588

8. Avigan M.I., Mozersky R.P., Seeff L.B. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int J Mol Sci. 2016; 17: 331. DOI: https://doi.org/10.3390/ijms17030331

9. Teschke R., Eickhoff A., Schwarzenboeck A., et al. Clinical review: herbal hepatotoxicity and the call for systematic data documentation of individual cases. J Liver Clin Res. 2015; 2: 1008. URL: http://wwwjscimed-central.com/Liver/liver-2-1008.pdf (date of access November 10, 2017)

10. Teschke R., Schulze J., Schwarzenboeck A., Eickhoff A., Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol. 2013; 25: 1093-8. DOI: https://doi.org/10.1097/MCG.0b013e3283603e89

11. Teschke R., Frenzel C., Schulze J., Schwarzenboeck A., Eickhoff A. Herbalife hepatotoxicity: evaluation of cases with positive reexposure tests. World J Hepatol. 2013; 5: 353-63.

12. Zambrone F.A.D., Correa C.L., Sampaio do Amaral L.M. A critical analysis of the hepatotoxicity cases described in the literature related to Herbalife products. Braz J Pharm Sci. 2015; 51. DOI: https://doi.org/10.1590/S1984-82502015000400004 (date of access November 10, 2017)

13. Wang F.S., Fan J.G., Zhang Z., Gao B., Wang H.Y. The global burden of liver disease; the major impact in China. Hepatology. 2014; 60: 2099-108.

14. Younossi Z.M., Stepanova M., Affendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9: 524-30.

15. Melchart D., Hager S., Albrecht S., Dai J., Weidenhammer W., Teschke R. Herbal traditional Chinese medicine and suspected liver injury: a prospective study. World J Hepatol. 2017; 18: 1141-57. DOI: https://doi.org/10.4254/wjh.v9.i29.1141

16. Cho J.H., Oh D.S., Hong S.H., et al. A nationwide study of the incidence rate of herb-induced liver injury in Korea. Arch Toxicol. 2017; 91: 4009-15.

17. Vega M., Verma M., Beswick D., et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf. 2017; 40: 783-7. DOI: https://doi.org/10.1007/s40264-017-0547-9

18. GBD 2013 Obesity Collaboration. Global, regional and national prevalence of overweight and obesity in children and adults 1980-2013: a systematic analysis. Lancet. 2014; 384: 766-81.

19. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289: 76-9.

20. Marseglia L., Manti S., D’Angelo G., et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci. 2015; 16: 378-400. DOI: https://doi.org/10.3390/ijms16010378

21. Teschke R., Schulze J., Eickhoff A., Wolff A., Frenzel C. Mysterious Hawaii liver disease case - Naproxen overdose as cause rather than Ox-yELITE Pro? J Liver Clin Res. 2015; 2: 1013. URL: http://www.jscimedcen-tral.com/Liver/liver-2-1013.pdf (date of access November 10, 2017)

22. Teschke R., Schwarzenboeck A., Frenzel C., Schulze J., Eickhoff A., Wolff A. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016; 15: 91-119. URL: http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTE-GIDO%20(1).pdf (date of access November 10, 2017)

23. Teschke R., Eickhoff A. The Honolulu liver disease cluster at the Medical Center: its mysteries and challenges. Int J Mol Sci. 2016; 17: 476. DOI: https://doi.org/10.3390/ijms17040476

24. Dhana K., Nano J., Ligthart S., et al. Obesity and life expectancy with and without diabetes in adults aged 55 years and older in the Netherlands: a prospective cohort study. PLoS Med. 2016; 13: e1002086. DOI: https://doi.org/10.1371/journal.pmed.1002086

25. Suzuki M., Willcox B., Willcox C. Okinawa Centenarian Study, 1976. URL: http://www.okicent.org/team.html (date of access November 10, 2017)

26. Chang Y., Jung H.S., Cho J., et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016; 111: 1133-40. DOI: https://doi.org/10.1038/ajg.2016.178

27. Targher G., Byrne C.D. Obesity: metabolic healthy obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2016; 13: 442-4. URL: https://www.nature.com/articles/nrgastro.2016.104 (date of access November 10, 2017)

28. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 4: 1313-21.

29. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107: 811-26. DOI: https://doi.org/10.1038/ajg.2012.128

30. Cholankeril G., Wong R.J., Hu M., et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017; 62: 2915-22.

31. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wimmer M. Fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73-84.

32. WHO. Obesity and Overweight. Fact Sheet, updated October 2017. URL: http://www.who.int/mediacentre/factsheets/fs311/en/ (date of access November 10, 2017)

33. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124-31.

34. Estes C., Razavi H., Loomba R., Younossi Z., Sanyal A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018; 67: 123-33.

35. Roytman M.M., Porzgen P., Lee C.L., et al. Letter to the Editor: outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am J Gastroenterol. 2014; 109: 1296-8.

36. Navarro V.J., Khan I., Bjornsson E., Seeff L.B., Serrano J., Hoofnagle J.H. Liver injury from herbal and dietary supplements. Hepatology. 2017; 65: 1363-73.

37. Teschke R., Danan G. Review article: diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016; 39: 729-44. DOI: https://doi.org/10.1007/s40264-016-0423-z

38. Teschke R., Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Exp Opin Drug Metab Toxicol. 2017; 13: 425-38.

39. Mazzanti G., Di Sotto A., Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol. 2015; 89: 1175-91.

40. R., Zhang L., Long H., et al. Traditional Chinese medicine and herbal hepatotoxicity: a tabular compilation of reported cases. Ann Hepatol. 2015; 14: 7-19.

41. Sarma D.N., Barrett M.L., Chavez M.L., et al. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf. 2008; 31: 469-84.

42. Frank J., George T.W., Lodge J.K., et al. Daily consumption of an aqueous green tea extract supplement does not impair liver function or alter cardiovascular disease risk biomarkers in healthy men. J Nutr. 2009; 139: 58-62. DOI: https://doi.org/10.3945/jn.108.096412

43. Isomura T., Suzuki S., Origasa H., et al. Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials. Eur J Clin Nutr. 2016; 70: 1221-9. DOI: https://doi.org/10.1038/ejcn.2016.78

44. Liss G., Lewis J.H. Drug-induced liver injury: what was new in 2008? Exp Opin Drug Metab Toxicol. 2009; 5: 843-60.

45. Teschke R., Zhang L., Melzer L., Schulze J., Eickhoff A. Green tea extract and the risk of drug-induced liver injury. Exp Opin Drug Metab Toxicol. 2014; 10: 1663-76. DOI: https://doi.org/10.1517/17425255.2014.971011

46. Elinav E., Pinkser G., Safadi R., et al. Association between consumption of Herbalife^® nutritional supplements and acute hepatotoxicity. J Hepatol. 2007; 47: 514-20.

47. Schoepfer A.M., Engel A., Fattinger K., et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol. 2007; 47: 521-6.

48. Stickel F., Droz S., Patsenker E., Bogli-Stuber K., Aebi B., Leib S.L. Severe hepatotoxicity following ingestion of Herbalife^® nutritional supplements contaminated with Bacillus subtilis. J Hepatol. 2009; 50: 111-17.

49. Johannsson M., Ormarsdottir S., Olafsson S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid. 2010; 96: 167-72. [Article in Icelandic]

50. Dara L., Hewett J., Lim J.K. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol. 2008; 14: 6999-7004.

51. Araujo J.L., Worman H.J. Acute liver injury associated with new formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep. 2015; 2015: 210303. DOI: https://doi.org/10.1136/bcr-2015-210303

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)